| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/09/2010 | US7659312 N-(4-sulfamoylphenyl)acetamide; modulates its transmembrane water transport properties |
| 02/09/2010 | US7659311 Delivery of agents such as heparin and calcitonin; greater efficacy; disodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid |
| 02/09/2010 | US7659310 Methods of enhancing solubility of agents |
| 02/09/2010 | US7659309 dissolving 1-{3-[3-(4-cyano-3-methoxy-phenyl)ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester in ethyl acetate with agitation, filtering, cooling the filtrate, seeding, isolation, drying |
| 02/09/2010 | US7659308 Concentricolide and its derivatives, process for preparing them, pharmaceutical composition comprising the same and its use |
| 02/09/2010 | US7659306 administering a therapeutically effective amount of nafadotride or a pharmaceutically acceptable salt for decreasing gastrointestinal tract motility or gastric emptying in a patient; sustained release agent |
| 02/09/2010 | US7659305 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. |
| 02/09/2010 | US7659304 Tryptophan derivative and application thereof |
| 02/09/2010 | US7659303 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders |
| 02/09/2010 | US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
| 02/09/2010 | US7659301 Controlling photoactivation; reducing oxygen concentration of tissue at site; prevention metabolism; cooling |
| 02/09/2010 | US7659300 2-(2-Oxo-3-pyridin-2-ylimidazolidin-1-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide; CGRP (Calcitonin Gene-Related Peptide); headache, migraine or cluster headache |
| 02/09/2010 | US7659299 Compounds inhibiting the binding of sap for treating osteoarthritis |
| 02/09/2010 | US7659298 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting |
| 02/09/2010 | US7659297 improved selectivity and pharmacokinetic properties; 6-Fluoro-1-[(1 H-indazol-4-yl)amino]-4,4-dimethyl-2-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene-2,5-diol; cyclization of imines |
| 02/09/2010 | US7659296 2-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid; 1-[4-(3,3-Dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-benzooxazole-6-carboxylic acid amide; stimulate bone formation, restore bone quality, acne, alopecia, Alzheimer's disease etc. |
| 02/09/2010 | US7659295 Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds |
| 02/09/2010 | US7659294 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| 02/09/2010 | US7659293 α-Amino-N-hydroxy-acetamide derivatives |
| 02/09/2010 | US7659291 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
| 02/09/2010 | US7659290 of nicardipine or its salts; use treating hypertension; storage stability; making injectable formulations by filling container with premix, adjusting pH and diluting |
| 02/09/2010 | US7659289 Hydroxyethylene-based β-secretase inhibitors and use thereof |
| 02/09/2010 | US7659288 5-aminoalkylpyrazole derivatives as pesticidal agents |
| 02/09/2010 | US7659287 Benzamide derivatives and uses related thereto |
| 02/09/2010 | US7659286 N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide |
| 02/09/2010 | US7659285 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| 02/09/2010 | US7659284 Thiazolopyridine kinase inhibitors |
| 02/09/2010 | US7659283 Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases |
| 02/09/2010 | US7659282 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 02/09/2010 | US7659281 HMG-CoA reductase inhibitors |
| 02/09/2010 | US7659280 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
| 02/09/2010 | US7659279 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer |
| 02/09/2010 | US7659278 Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases |
| 02/09/2010 | US7659276 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine; G-protein coupled receptor antagonist; antidepressant, anxiolitic agent, obesity |
| 02/09/2010 | US7659275 Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| 02/09/2010 | US7659274 Unsaturated mTOR inhibitors |
| 02/09/2010 | US7659273 Composition for accelerating bone fracture healing |
| 02/09/2010 | US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders |
| 02/09/2010 | US7659271 N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) |
| 02/09/2010 | US7659270 (1R)-2-((2S)-2-(5-(6-(4-(2-((2S)-1-((2R)-2-(dimethylamino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)phenyl)-3-pyridinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) -N,N-dimethyl-2-oxo-1-phenylethanamine; inhibit the function of the non-structural proteins (NS5A) |
| 02/09/2010 | US7659269 Substituted indolealkanoic acids |
| 02/09/2010 | US7659268 Modulators of ATP-binding cassette transporters |
| 02/09/2010 | US7659267 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding |
| 02/09/2010 | US7659266 N1-[(3S)-2-hydroxytetrahydrofuran-3-yl]-N2-[imino(10H-phenothiazin-2-yl)methyl]-L-leucinamide; (3S)-3-({N-[imino(10H-phenothiazin-2-yl)methyl]-L-leucyl}amino)tetrahydrofuran-2-yl acetate; hearing disorders, muscular dystrophy |
| 02/09/2010 | US7659265 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbothioamide; menopause therapy; contraceptive; anticancer agents |
| 02/09/2010 | US7659264 CGRP receptor antagonists |
| 02/09/2010 | US7659263 (E)-3-[4-({1-[(11-cyclohexyl-8-methoxy-4,5-dihydro-6-oxa-1-thia-3b-azabenzo[e]cyclopenta[a]azulene-2-carbonyl)amino]cyclobutanecarbonyl}amino)phenyl]acrylic acid; RNA-dependent RNA polymerase inhibitory activity; hepatitis C |
| 02/09/2010 | US7659262 Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di-amino acid salts, and mono- and di-amino acid ester salts |
| 02/09/2010 | US7659261 combretastatin A4 phosphate mono-tromethamine in crystalline solid state; salt form increases solubility of combretastatin A4; regenerates native combretastatin A-4 in vivo and do not produce unwanted or potentially deleterious side products when undergoing regeneration |
| 02/09/2010 | US7659260 Heavy water, a glycosaminoglycan such as chondroitin sulfate; administering to the vitreous cavity of the eye for retinal repair |
| 02/09/2010 | US7659259 Method of treating inflammation of the eye |
| 02/09/2010 | US7659258 A DNA segment with amino acid, phosphorothioate or phosphoroamidate linkages capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene; osteoporosis, periodontal disease, Paget's Disease, Antiarthritic agents; breast and prostate cancer |
| 02/09/2010 | US7659257 Medicament for treating lung cancer |
| 02/09/2010 | US7659256 Combination therapy for effecting weight loss and treating obesity |
| 02/09/2010 | US7659254 Abuse-resistant amphetamine prodrugs |
| 02/09/2010 | US7659253 Abuse-resistant amphetamine prodrugs |
| 02/09/2010 | US7659242 Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities |
| 02/09/2010 | US7659228 Synergistic insecticide mixtures |
| 02/09/2010 | US7659115 Nucleic acid encoding human transductin-1 polypeptide |
| 02/09/2010 | US7659079 Selectively binding and/or detecting an aggregating abnormal form of a prion protein in the presence of non-aggregating normal form of the protein; brain disorder |
| 02/09/2010 | US7659076 Binding of pathological forms of prion proteins |
| 02/09/2010 | US7659061 vehicle comprising a modified and an unmodified liquid carrier with ratio of modified to unmodified of 0.00001:99.99999 to less than 0.01:99.99; one to three bioactive agents may be released on a predictable sustained basis. |
| 02/09/2010 | US7658952 Dialysis solutions containing pyrophosphates |
| 02/09/2010 | US7658949 Surface modification of lactose excipient for use in powders for inhalation |
| 02/09/2010 | US7658945 Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof |
| 02/09/2010 | US7658944 Gemfibrozil, fenofibrate, bezafibrate, clofibrate, ciprofibrate and active metabolites and analogues dissolved in a vehicle, which is hydrophobic, hydrophilic or water-miscible; improved bioavailability of the active ingredient upon oral administration |
| 02/09/2010 | US7658943 Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
| 02/09/2010 | US7658941 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 02/09/2010 | US7658939 Inert core, first layer comprising naltrexone, nalmefene or salts; and second hydrophobic layer; pain treatment |
| 02/09/2010 | US7658937 exposing the parasite Brugia malayi, which causes lymphatic filariasis, to an inhibitory amount of a hydroxy substituted anthraquinone selected from 1-methyl-2,3-dihydroxy anthraquinone, 1-methyl-2,3,8-trihydroxy anthraquinone, 1-hydroxy-2,8-dimethoxy-3-methyl anthraquinone |
| 02/09/2010 | US7658917 A beta aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural beta amyloid peptides when contacted with the peptides. |
| 02/09/2010 | US7658916 Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| 02/09/2010 | US7658914 first container containing a dry formulation of polyoxyethylene glycol , ascorbic acid and sodium sulfate, calcium sulfate and sodium chloride, potassium chloride, second container containing dry ascorbic acid or sodium or potassium salt; also contains flavor, sweetener; for colonoscopy preperation |
| 02/09/2010 | US7658768 Calcium sulfate hemihydrate, accelerant (calcium sulfate dihydrate), plasticizing material, mixing solution, demineralized bone matrix, water; filler for voids and/or defects defined by bone |
| 02/09/2010 | CA2663141C Creatine pyroglutamic acid salts and methods for their production and use in individuals |
| 02/09/2010 | CA2625906C Lazaroids-based compositions and methods for preventing adhesion formation using the same |
| 02/09/2010 | CA2614926C Crystal modification c of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| 02/09/2010 | CA2613061C Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 02/09/2010 | CA2573413C Histone deacetylase inhibitors |
| 02/09/2010 | CA2570103C Method of increasing growth hormone secretion |
| 02/09/2010 | CA2557576C Novel benzothiazepine and benzothiepine compounds |
| 02/09/2010 | CA2530788C Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| 02/09/2010 | CA2485977C Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane |
| 02/09/2010 | CA2484954C 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors |
| 02/09/2010 | CA2483597C New pharmaceutical compositions containing flibanserin polymorph a |
| 02/09/2010 | CA2482320C Methods for modulating phototoxicity |
| 02/09/2010 | CA2473394C Semi-fluorinated alkanes and their use |
| 02/09/2010 | CA2471265C Pyrimidotriazines as phosphatase inhibitors |
| 02/09/2010 | CA2466720C Medicament for the treatment of viral skin and tumour diseases |
| 02/09/2010 | CA2466372C Non-human transgenic mammals used as models for human pathologies originating from stem cells |
| 02/09/2010 | CA2451562C Piperazine compound |
| 02/09/2010 | CA2451240C Cyclic diamine compound with 6 membered ring groups |
| 02/09/2010 | CA2440760C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 02/09/2010 | CA2440588C Chronotherapeutic dosage forms |
| 02/09/2010 | CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications |
| 02/09/2010 | CA2438704C Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof |
| 02/09/2010 | CA2437505C Isoxazoline derivatives as anti-depressants |
| 02/09/2010 | CA2434962C Use of isovaleryl l-carnitine for the treatment of fractures |
| 02/09/2010 | CA2431079C Method and composition for the treatment of diabetic neuropathy |
| 02/09/2010 | CA2430827C Coniosetin and derivatives thereof, process for the preparation and the use thereof |